Summary: The aim of this open-label, randomized, and 3-period crossover study was to evaluate the influences of concomitant antacid administration on the plasma disposition, intestinal absorption, and urinary excretion of gabapentin in humans. Gabapentin (200 mg) was orally administered alone, with 1 g magnesium oxide (MgO), or with 20 mg omeprazole to 13 healthy adult subjects. Oral bioavailability (BA) of gabapentin was estimated by 24-h urine collection. The C max , T max and AUC 0¨o f gabapentin + MgO were significantly lower than that of gabapentin alone (by 33%, 36% and 43%, respectively) and gabapentin + omeprazole (by 29%, 46% and 40%, respectively). In contrast, no significant differences were observed in the plasma disposition parameters of gabapentin between the treatments with and without omeprazole. The gabapentin BA in the MgO treatment was significantly lower, by 32% and 39%, compared to the gabapentin alone and with omeprazole treatment, respectively. There was no significant difference in the gabapentin BA between the gabapentin alone and with omeprazole treatment. Concomitant MgO and omeprazole did not affect the renal clearance of gabapentin. In conclusion, concomitant MgO decreased the gabapentin exposure through the reduction of intestinal absorption extent and rate. This reduction may be independent of the suppression of gastrointestinal acidification caused by antacids.
Introduction
Gabapentin is a broad-spectrum anti-epileptic drug that is structurally similar to È-aminobutyric acid. 1¥ It is approved for adjunctive therapy for the treatment of partial seizures. 2¥ In addition, gabapentin is used to treat neuropathic pain caused by diabetic and cancer neuropathy and post-herpetic neuralgia.
3,4¥ Evidence is increasing regarding the efficacy of gabapentin in the treatment of neuropathic pain. Gabapentin was found to be effective at improving analgesia in patients with neuropathic cancer pain receiving opioids. 5¥ Although the precise mechanism of the pharmacological action of gabapentin in neuropathic pain is unclear, the analgesic effects are believed to involve inhibition of the release of glutamate from pre-synaptic terminals. 6¥ Gabapentin is absorbed from the intestine after oral administration and is completely excreted into the urine in an unchanged form. 7¥ The oral bioavailability ¤BA¥ of gabapentin is approximately 57% after a single dose of 300 mg in healthy subjects. 8¥ This phenomenon implies the involvement of an active and saturable intestinal transport mechanism. Gabapentin binds only slightly to plasma protein ¤unbound fraction h 97%¥. 9¥ Thus, the plasma disposition of gabapentin is believed to be dependent on its intestinal absorption and the glomerular filtration rate.
Concomitant administration of gabapentin and an antacid containing aluminum hydroxide and magnesium hydroxide has been found to decrease the maximum plasma concentration ¤C max ¥ and area under the concentration-time curve ¤AUC¥ of gabapentin in healthy subjects. 10¥ Although the exact mechanism of the interaction has not been determined in humans, Neurontin ¬ ¤gabapentin¥ product information recommends avoiding simultaneous dosing with antacids containing these metal cations. It remains to be clarified if the reduction is associated with either the formation of a chelate complex or the suppression of gastrointestinal acidification caused by antacids. In addition, there are no clinical data on the influence of antacids containing these metal cations on the intestinal absorption and urinary excretion of gabapentin.
Cancer patients receiving gabapentin for neuropathic pain are often also administered magnesium oxide ¤MgO¥ at the same time to treat opioid-induced constipation. 11¥ In addition, the dose of MgO is self-adjusted by the patient according to bowel movement frequency and stool hardness. Proton pump inhibitors ¤PPIs¥ suppress gastric acidification more potently than antacids containing metal cations. Omeprazole is commonly used for the treatment of ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. 12¥ If gastrointestinal pH affects the intestinal absorption of gabapentin, concomitant omeprazole may also affect the intestinal absorption of gabapentin in clinical settings.
The pharmacokinetic interaction between gabapentin and antacids has not been fully evaluated in clinical settings. Elucidation of the interaction mechanism may contribute to the optimization of cancer pain management. The aim of the present randomized and 3-period crossover clinical pharmacokinetic trial in healthy adult subjects was to evaluate the influences of concomitant administration of gabapentin and MgO, and gabapentin and omeprazole on the plasma disposition, intestinal absorption, and urinary excretion of gabapentin.
Methods

Ethics and subjects:
This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki ¤Revised Edinburgh, 2000¥ and in accordance with all International Conference on Harmonization and Good Clinical Practice guidelines. The protocol and informed consent documentation was reviewed and approved by the Ethics Committee of Hamamatsu University Hospital. Each patient received information about the scientific aim of the study. Written informed consent was obtained from 15 healthy male subjects.
Study design:
This study was an open-label, randomized and 3-period crossover trial ¤UMIN-CTR, UMIN000002708¥ conducted at a single site ¤Translational Research Center of Hamamatsu University Hospital, Shizuoka, Japan¥. There was a minimum 21-day washout period between the treatments. In all treatment arms, the participants received a single oral dose of 200 mg gabapentin ¤Gabapen ¬ Tablet, Pfizer Japan Inc., Tokyo, Japan¥ after an overnight fast of 12 h. Gabapentin treatment alone was 200 mg gabapentin without a concomitant drug. Concomitant MgO treatment consisted of a single oral administration of 1 g MgO ¤Magmitt ¬ Tablet, Kyowa Chemical Industry Co., Ltd., Kagawa, Japan¥ together with 200 mg gabapentin and concomitant omeprazole treatment consisted of oral administration of 20 mg omeprazole ¤Omepral ¬ Tablet, AstraZeneca K.K., Osaka, Japan¥ at 12 h and 30 min before 200 mg gabapentin. To standardize the conditions, subjects were not allowed to eat or drink for 3 h following dosing and then were required to drink at least 1,000 mL of natural water ¤hardness, 25.5 mg/L¥ within 12 h. To ensure full compliance, all doses of study medication were administrated under medical supervision. Sample collection: Blood samples ¤5 mL¥ for the determination of gabapentin and omeprazole were drawn into EDTA tubes at 0, 1, 2, 4, 6, 9, 12, and 24 h after a single administration of gabapentin in each treatment arm. Twenty-four hour cumulative urine after gabapentin administration was collected on the same day as blood sampling.
Bioanalytical methods: Gabapentin was purchased from Toronto Research Chemicals Inc. ¤North York, Ontario, Canada¥. Baclofen as an internal standard and 4-fluoro-7-nitro-benzofurazan as a fluorescent derivatization reagent were obtained from Wako Pure Chemicals ¤Osaka, Japan¥ and Dojindo Laboratories ¤Kumamoto, Japan¥, respectively. Plasma and urine specimens obtained by the centrifugation of blood and urine, respectively, at 1,670 ' g at 4ôC for 10 min were stored at %80ôC until sample preparation. Gabapentin concentrations in the plasma and urine were determined with isocratic fluorometric HPLC as previously described. 13¥ Calibration curves in human plasma and urine were linear over the concentration ranges of 0.05®10 and 10®1,000 µg/mL, respectively. Intra-and inter-assay precision and accuracy values of plasma were within 8.0% and 101®109% and within 8.3% and 94®108%, respectively, while those of urine were within 8.5% and 97®106% and within 9.5% and 97®105%, respectively. Plasma concentrations of omeprazole were determined using an HPLC-UV method as previously described. 14¥ Calibration curves in human plasma were linear over the concentration range of 0.01®3 µg/mL. Intra-and inter-assay precision and accuracy values of plasma were within 9.2% and 97®105% and within 10.3% and 98®107%, respectively.
Safety: Adverse reaction monitoring, vital sign measurements, physical examination findings, and clinical laboratory tests were performed in each treatment arm. The severity grade for an adverse reaction was categorized using Common Terminology Criteria for Adverse Events ¤CTCAE¥ version 4.0. The relationship between an adverse event and the treatment was determined by the investigator.
Pharmacokinetic analysis: Pharmacokinetic parameters for gabapentin and omeprazole were calculated using a non-compartmental pharmacokinetic method using Phoenix WinNonlin ¤v 6.1, Pharsight Corporation, Mountain View, CA¥ based on individual concentration-time profiles. The C max and its time ¤T max ¥ were estimated directly from experimental data. The AUCs of gabapentin and omeprazole from 0 h to infinity ¤AUC 0®W ¥ were determined by the linear trapezoidal method. The apparent elimination half-life ¤T 1/2 ¥ was calculated as ¤ln 2¥ k e %1 , where k e is the slope of the log-linear regression of the terminal phase of the concentration versus time curve. BA of gabapentin was estimated from the equation: BA ¤%¥ © amount of gabapentin in ¤cumulative urine/200 mg gabapentin¥ ' 100. Renal clearance of gabapentin ¤CL GP ¥ was calculated from the equation: CL GP © amount of gabapentin in 24-h urine/ AUC 0®W of gabapentin. Creatinine clearance ¤CL CR ¥ was calculated using the values measured by 24-h urine collection.
Statistical analysis:
All statistical analyses were performed using SPSS ¤15.0J, SPSS Japan Inc., Tokyo, Japan¥. The pharmacokinetic parameters and urine pH between three treatments were compared using a one-way repeated measures analysis of variance and post-hoc paired t-test. The relationships between the adverse reactions and each treatment were tested using Fisherös exact test. Pharmacokinetic data and urine pH are expressed as the mean + standard deviation ¤SD¥. Statistical data are expressed as the mean difference and its 95% confidence interval ¤95% CI¥. The pharmacokinetic data for omeprazole are expressed as the median and interquartile range ¤IQR¥ because normal distribution could not be assumed for interindividual variation. A p g 0.05 was considered to indicate statistical significance.
Results
Demographic characteristics:
After enrollment, two subjects were excluded because they declined to receive the study medication just before treatment. Thus, 13 healthy male adult subjects aged 22 to 35 years completed the study protocol. No subjects had received any medication or supplement for one week preceding the treatment. The present study was performed in a Japanese population. The mean body mass index was 22 m 2 /kg. No subject had hepatic or renal function impairment, based on laboratory tests ¤Table 1¥.
Plasma disposition of gabapentin and omeprazole: Figure 1 and Table 2 show the plasma concentration-time profiles of gabapentin over a period of 24 h for each treatment after gabapentin administration and its kinetic parameters in healthy subjects. The C max , T max and AUC 0®W of gabapentin when given together with MgO were significantly lower, by 33%, 36% and 43%, respectively, than those for gabapentin alone ¤Fig. 2¥. The 95% CIs of the mean difference ¤alone % MgO¥ in the C max , T max and AUC 0®W were 0.39 to 1.19 µg/mL, 0.48 to 1.98 h and 5.32 to 12.5 µg&h/mL, respectively ¤Table 3¥. In contrast, no significant differences were observed in the C max , T max and AUC 0®W of gabapentin between the gabapentin alone and omeprazole treatments. The C max , T max and AUC 0®W of gabapentin when administered with MgO were also significantly lower, by 29%, 46% and 40% respectively, than those for omeprazole treatment. The 95% CIs of the mean difference ¤MgO % omeprazole¥ in the C max , T max and AUC 0®W were %1.09 to %0.24 µg/mL, %2.60 to %1.10 h and %11.6 to %3.87 µg&h/mL, respectively. Concomitant gabapentin with MgO and with omeprazole did not affect the T 1/2 of gabapentin. The C max and T max of omeprazole ¤median and IQR¥ were 661 and 534 to 934 ng/mL and 2.5 and 1.5 to 2.5 h in healthy subjects, respectively. The median and IQR of omeprazole AUC 0®W were 1,698 and 1,212 to 2,490 ng&h/mL. Oral bioavailability and urinary excretion of gabapentin: Table 4 shows the influences of concomitant MgO and concomitant omeprazole on the BA and urinary excretion of gabapentin in healthy subjects. The BA of gabapentin when given with MgO was significantly lower, by 32%, compared to that for gabapentin alone ¤Fig. 3¥. The 95% CI of the mean difference ¤alone % MgO¥ in gabapentin BA was 11.2 to 25.4% ¤Table 5¥. In contrast, no significant difference was observed in the gabapentin BA between the gabapentin alone and gabapentin ¦ omeprazole treatments. The BA of gabapentin in the gabapentin ¦ MgO treatment was also significantly decreased by 39% compared to gabapentin ¦ omeprazole treatment. The 95% CI of the mean difference ¤MgO % omeprazole¥ in gabapentin BA was %39.0 to %11.6%. Concomitant MgO and omeprazole did not affect the CL GP ¤Fig. 3¥. In addition, there was no significant difference in the ratio of CL GP to CL CR between treatments.
Urine pH: The 24-h urine pH values in the gabapentin alone, gabapentin ¦ MgO, and gabapentin ¦ omeprazole treatments were 6.5 + 0.6, 7.0 + 0.6, and 6.3 + 0.6 ¤mean + SD¥, respectively. Urine pH in the MgO treatment was significantly higher than that in the other 2 treatments. The 95% CI of the mean difference ¤alone % MgO and MgO % omeprazole¥ in urine pH was %1.01 to%0.06 and 0.20 to 1.19, respectively. Data are expressed as mean difference with 95% confidence interval in parentheses. Alone, gabapentin aline; MgO, with magnesium oxide treatment; omeprazole, with omeprazole treatment; C max , maximum plasma concentration; T max , time to maximum plasma concentration; AUC 0®W , area under the plasma concentrationtime curve from time 0 to infinity; and T 1/2 , apparent terminal half-life. *p g 0.05. Safety and tolerability: All adverse reactions were mild and all were resolved without intervention in this population. Adverse reactions not exceeding grade 2 were experienced by 8 subjects during gabapentin alone treatment, 7 subjects during MgO treatment, and 8 subjects during omeprazole treatment. The most frequent adverse reaction was drowsiness ¤5, 6 and 6 subjects during gabapentin alone, MgO and omeprazole treatment, respectively¥. Headache was also observed in 2 subjects in the gabapentin alone treatment and in one subject each in the omeprazole and MgO treatments. Concomitant MgO and omeprazole did not significantly affect the incidences of drowsiness and headache. Other single adverse reactions included the lack of motivation, diarrhea, itching, and malaise. There were no clinically significant changes in vital signs or physical examination findings during the treatments.
Discussion
Many cancer patients receiving gabapentin for neuropathic pain are also given MgO to treat opioid-induced constipation. 11¥ Although concomitantly administered antacids containing aluminum hydroxide and magnesium hydroxide decrease gabapentin exposure in healthy subjects, 10¥ the pharmacokinetic interactions associated with other antacids have not been fully evaluated in humans. The present study evaluated the influences of concomitant administration of gabapentin and MgO and gabapentin and omeprazole on the plasma disposition, intestinal absorption, and urinary excretion of gabapentin in healthy subjects. Concomitant MgO affected the exposure to gabapentin through the reduction of intestinal absorption. In contrast, concomitant omeprazole altered neither the plasma disposition nor intestinal absorption of gabapentin. These antacids did not affect the urinary excretion of gabapentin. To the best of our knowledge, this is the first report to evaluate the influences of antacids on intestinal absorption and urinary excretion of gabapentin together with plasma disposition in humans.
The plasma disposition parameters for the gabapentin only group were similar to those in earlier reports.
8,15,16¥
Concomitant gabapentin ¦ MgO administration decreased the C max and AUC 0®W of gabapentin by 33% and 43%, respectively. Neurontin ¬ product information states that concomitant administration of an antacid containing aluminum hydroxide and magnesium hydroxide decreases the gabapentin C max by 17% and the AUC 0®W by 20% in healthy subjects. 10¥ Gabapentin is absorbed rapidly from intestine after oral administration and is excreted in unchanged form in the urine. 7¥ Our results suggest that concomitant MgO may alter the intestinal absorption or urinary excretion of gabapentin. Possible mechanisms for the reduction in intestinal absorption include the suppression of gastrointestinal acidification or the formation of a chelate complex. In contrast, concomitant administration of gabapentin with omeprazole, which more potently suppresses gastric acidification, did not alter the C max or AUC 0®W of gabapentin. This result indicates that the suppression of gastrointestinal acidification did not affect the reduction of gabapentin exposure. In addition, the prolonged T max of gabapentin when given together with omeprazole might be dependent on a delay in gastric emptying rate. Rasmussen et al. also reported that omeprazole induces a delay in gastric emptying of both liquid and solid. 17¥ In contrast, T max of gabapentin when given together with MgO was shorter than that for gabapentin alone. Although the influence of concomitant MgO on gastric emptying rate is unclear, this result indicated that concomitant MgO accelerated the gastric emptying rate.
Concomitant MgO administration decreased the BA, C max and AUC 0®W of gabapentin in the present study. The reduction of gabapentin BA corresponded closely to that of the AUC 0®W with concomitant MgO administration. In contrast, the gabapentin BA did not change with concomitant omeprazole administration. The gastrointestinal pH after administration of omeprazole was not evaluated in this study. Furuta et al. lizers. 18¥ In this study, the pharmacokinetic profile of omeprazole suggest that ten of the enrolled volunteers were intermediate or poor metabolizers. In addition, they received 20 mg omeprazole at 12 h and 30 min before gabapentin administration. Therefore, we considered that omeprazole provided enough action in this study design. Our results confirmed that the intestinal absorption of gabapentin was independent of gastrointestinal pH. Concomitant antacid administration did not significantly affect the CL GP . This result indicates that the urinary excretion of gabapentin did not influence the reduction of gabapentin exposure with concomitant MgO administration. The reduction of gabapentin exposure was associated with its intestinal absorption.
The BA, CL GP , and AUC 0®W of gabapentin varied among healthy subjects. The organic cation transporters OCTN1 and OCT2 may contribute to interindividual variations in the pharmacokinetics of gabapentin.
19, 20¥ Urban et al. reported that common variants of OCTN1 contributed to variation in the urinary excretion of gabapentin. Lal et al. demonstrated that concomitant cimetidine, an OCT2 substrate, decreased the CL GP by 18%. 20¥ These transporters express at the apical membrane in intestine and kidneys and are involved in the absorption and excretion of gabapentin.
19,21¥ OCTN1 has been demonstrated to be a pH-dependent organic cation transporter. 22¥ At first, we speculated that the pharmacokinetic interaction with antacids was caused by the suppression of gastrointestinal acidification through a pHdependent organic cation transporter; however, concomitant omeprazole administration did not alter the BA. In addition, concomitant antacid administration did not affect the CL GP . In the present study, there was no clinical evidence of a pH-dependent interaction with antacids. However, the variation in the CL GP in MgO treatment ¤coefficient of variation, 38%¥ was larger than that for gabapentin treatment alone ¤28%¥. Concomitant MgO increased the urine pH, a finding that was also reported by Allie et al. 23¥ A higher urine pH may have caused the slightly larger variation in urinary excretion of gabapentin through a pH-dependent organic cation transporter.
Concomitant MgO may affect neuropathic cancer pain through the reduction of gabapentin exposure. Gabapentin exhibits a dose-response relationship in the treatment of neuropathic pain.
1,2¥ There are frequent opportunities for the combination of MgO with gabapentin in clinical settings. In addition, the MgO dose is not fixed and is self-adjusted by the patient according to bowel movement frequency and stool hardness. Fluctuations in gabapentin exposure may lead to poor patient satisfaction with pain medication. Neurontin ¬ product information states that the reduction of gabapentin exposure improves when gabapentin is administered 2 h after administration of an antacid containing metal cations.
10¥ Thus, it may be possible to avoid the interaction by delaying the administration of gabapentin until 2 h after MgO dosing.
One half of the enrolled subjects experienced adverse reactions that were less than grade 2 in severity. The major adverse reactions reported were drowsiness and headache. Concomitant MgO and omeprazole did not have any effects on the incidences of drowsiness and headache. Gabapentin possesses higher dose tolerability compared with other anti-epileptic drugs. 24¥ All adverse reactions observed were resolved without treatment. The incidence of adverse reactions to gabapentin in the present study was lower than that in earlier reports, 25,26¥ most likely because the enrolled subjects received a lower dose of gabapentin. There may have been few problems due to adverse reactions because of the reduction of gabapentin exposure.
Cancer patients may exhibit different pharmacokinetic profiles compared to healthy subjects. Concomitant opioid administration decreases gastrointestinal motility 27¥ and may influence the intestinal absorption of gabapentin. Most patients with cancer neuropathic pain are elderly and have renal dysfunction. McLean reported that the BA after a single dose of gabapentin was 57% at 300 mg and 42% at 600 mg in healthy subjects. 8¥ Intestinal absorption of gabapentin may have been less saturated at the dose of 200 mg used in the present study. Our study has demonstrated that concomitant administration of MgO has an effect on the pharmacokinetics of gabapentin in situations with less saturable intestinal absorption. More definitive conclusions will likely be obtained in future clinical studies with cancer pain patients. In addition, we considered the possibility that the reduction of gabapentin exposure caused by concomitant MgO was associated with the formation of chelate complex based on the results of the present study; however, further in vitro study is needed to elucidate the mechanism.
In conclusion, concomitant gabapentin and MgO administration had an effect on gabapentin exposure through a reduction of its intestinal absorption extent and rate. Concomitant gabapentin and omeprazole administration did not alter either the plasma disposition or intestinal absorption of gabapentin. This reduction caused by concomitant MgO was not associated with the suppression of gastrointestinal acidification caused by antacids.
